Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders

Br J Haematol. 2016 Nov;175(3):359-364. doi: 10.1111/bjh.14321. Epub 2016 Sep 9.

Stephen P Mulligan^{1

2}, Christopher M Ward^{3

4}, David Whalley^{3

5}, Sarah N Hilmer^{3

6}

¹ Department of Haematology, CLL Unit, Sydney, Australia. mulligan@sydney.edu.au.
² Kolling Research Institute, University of Sydney, Sydney, Australia. mulligan@sydney.edu.au.
³ Kolling Research Institute, University of Sydney, Sydney, Australia.
⁴ Department of Haematology, Haemostasis Unit, Sydney, Australia.
⁵ Department of Cardiology, Electrophysiology Unit, Sydney, Australia.
⁶ Department of Clinical Pharmacology and Aged Care, Royal North Shore Hospital, Sydney, Australia.

No abstract available

Keywords: atrial fibrillation; chronic lymphocytic leukaemia; drug interactions; ibrutinib; stroke prophylaxis.

Publication types